Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|October 28, 2021
- October 2021
- Volume 87
- Issue 10
Pet Peeves: October 2021
Advertisement
Impatient Patient
People who come early before their appointment for covid test and get mad they have to wait.
A Tight Squeeze
People who ask for items that don’t fit through the drive-through.
A Family Affair
When customers ask you to look up another family member after you just rang them out.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
almost 5 years ago
OTC Case Studies: Inflammatory Bowel Diseasealmost 5 years ago
Moms Are Not OK: Understand, Recognize, and Treat Postpartum Depressionalmost 5 years ago
Generics and Biosimilars Have Critical Differencesalmost 5 years ago
Case Studies: October 2021almost 5 years ago
Clinical Pharmacology Update: Brexafemme From Scynexis, Incalmost 5 years ago
October 2021 OTC Product Newsalmost 5 years ago
CGM Improves Outcomes for Patients Using Only Basal Insulinabout 5 years ago
Pharmacies Play Key Role as Center of Immunization ServicesAdvertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
3
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
4
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
5